Skip to main content
SpringerLink
Log in

Fundamentals of Cancer Treatment

Effects of Chemotherapy on Neoplastic Cells

  • Chapter
Book cover Cancer in the Spine

Part of the book series: Current Clinical Oncology ((CCO))

  • 1124 Accesses

Abstract

Cytotoxic chemotherapy evolved from the concepts of Lissauer and Ehrlich over the last century. The initial chemotherapy protocols they devised were characterized by a lack of specificity, and walking a fine line balancing the toxicities experienced by the host and the tumor. This has been subsequently improved owing to a better understanding of tumor biology and the biochemical basis of action of the chemotherapy regimens. Radiation therapy started after the discovery of X-rays by Roentgen in 1895. Refinement of these modalities has resulted in therapeutic options for patients with several types of malignancies. Innovative modern techniques in the 1990s have provided insight into the intracellular pathways that result in sensitivity and resistance of the neoplastic cells to drug treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tannock IF. Cell kinetics and chemotherapy. A critical review. Cancer Treat Rep 1978; 62:1117–1133.

    PubMed  CAS  Google Scholar 

  2. Young RC, De Vita VT. Cell cycle characteristics of human solid tumors in vivo. Cell Tissue Kinet 1970; 3:285–290.

    PubMed  CAS  Google Scholar 

  3. Alberts DS. A unifying vision of cancer therapy for the 21st century. J Clin Oncol 1999; 17:13–21.

    PubMed  CAS  Google Scholar 

  4. Yankee RA, De Vita VT, Perry S. The cell cycle of leukemia L 1210 cells in vivo. Cancer Res 1968; 27:2381–2385.

    Google Scholar 

  5. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents XII: on the criteria and kinetics associated with “curability of leukemia”. Cancer Chemother Rep 1964; 35:1–111

    PubMed  CAS  Google Scholar 

  6. Schnipper L. Clinical implications of tumor-cell heterogeneity. N Engl J Med 1986; 314:1423–1431.

    PubMed  CAS  Google Scholar 

  7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70.

    Article  PubMed  CAS  Google Scholar 

  8. Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol 1989; 28:113–121.

    Article  PubMed  CAS  Google Scholar 

  9. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408–1416.

    PubMed  CAS  Google Scholar 

  10. Nowell PC. The clonal evolution of tumor progression. Science 1976; 194:23–28.

    Article  PubMed  CAS  Google Scholar 

  11. Nowell P: Mechanisms of tumor progression. Cancer Res 1986; 46:2203–2207.

    PubMed  CAS  Google Scholar 

  12. Steel GG. The growth kinetics of tumors in relation to their therapeutic response. Laryngoscope 1975; 85:359–370.

    Article  PubMed  CAS  Google Scholar 

  13. Coldman AJ, Goldie JH. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987; 14:29–33.

    PubMed  CAS  Google Scholar 

  14. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70:163–169.

    PubMed  CAS  Google Scholar 

  15. Norton LA. A gompertzian model of human breast cancer growth. Cancer Res 1988; 48:7067–7071.

    PubMed  CAS  Google Scholar 

  16. Steel GG, Adams GE, Peckham MJ, eds. The Biologic Basis of Radiotherapy. The Netherlands: Elsevier; 1983:239–248.

    Google Scholar 

  17. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14:2590–2611.

    PubMed  CAS  Google Scholar 

  18. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualization in cancer chemotherapy. Drugs 1998; 56:1019–1038.

    Article  PubMed  CAS  Google Scholar 

  19. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998; 34:1493–1499.

    Article  PubMed  CAS  Google Scholar 

  20. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990; 8:1739–1753.

    PubMed  CAS  Google Scholar 

  21. Wagner JG. Kinetics of Pharmacologic Response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 1968; 20:173–201.

    Article  PubMed  CAS  Google Scholar 

  22. Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989; 58:137–171.

    Article  PubMed  CAS  Google Scholar 

  23. Goldstein LJ, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human tumors. J Natl Cancer Inst 1989; 81:116–124.

    Article  PubMed  CAS  Google Scholar 

  24. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996; 32A:921–926.

    Article  PubMed  CAS  Google Scholar 

  25. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187:127–137.

    Article  PubMed  CAS  Google Scholar 

  26. Moolgavkar SH, Knudsen AG. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 1981; 66:1037–1052.

    PubMed  CAS  Google Scholar 

  27. Fearon EC. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997; 278:1043–1058.

    Article  PubMed  CAS  Google Scholar 

  28. Sikic BL. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11:1629–1635.

    PubMed  CAS  Google Scholar 

  29. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med 1973; 228:998–1006.

    Google Scholar 

  30. Skipper HE. Critical variables in the design of combination chemotherapy regimens to be used alone or in adjuvant settings. Colloque INSERM 1986; 137:11.

    Google Scholar 

  31. Hyrniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987:14:65–74.

    Google Scholar 

  32. Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986; 46:3876–3885.

    PubMed  CAS  Google Scholar 

  33. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment of solid tumors. J Natl Cancer Inst 2000; 92:205–216.

    Article  PubMed  CAS  Google Scholar 

  34. Frei E III. Curative cancer chemotherapy. Cancer Res 1985; 45:6523–6537.

    PubMed  Google Scholar 

  35. Krakoff IH. Systemic treatment of cancer. CA Cancer J Clin 1996; 46:137–141.

    Article  Google Scholar 

  36. Rideout DC, Chou TC. Synergism, potentiation and antagonism in chemotherapy. An overview. In: Chou TC, Rideout DC, eds. Synergism and Antagonism in Chemotherapy. San Diego, CA: Academic Press; 1991:3.

    Google Scholar 

  37. Henderson IC, Gelman RS, Harris JR, Canellos GP. Duration of therapy in adjuvant chemotherapy trials. NCI Monogr 1986; 1:95–98.

    PubMed  Google Scholar 

  38. Hellman S. Stopping metastases at their source. N Engl J Med 1997; 337:996–997.

    Article  PubMed  CAS  Google Scholar 

  39. Collins M. Pharmacokinetic rationale for regional drug delivery. J Clin Oncol. 1984; 2:498–504.

    PubMed  CAS  Google Scholar 

  40. Perry MC, ed. The Chemotherapy Sourcebook. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH

    Sujith Kalmadi MD & Derek Raghavan MD

Authors
  1. Sujith Kalmadi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derek Raghavan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lerner College of Medicine and The Cleveland Clinic Spine Institute Department of Orthopaedic Surgery, The Cleveland Clinic Foundation, Cleveland, OH

    Robert F. McLain MD

  2. The Cleveland Clinic Spine Institute, The Cleveland Clinic Foundation, Cleveland, OH

    Kai-Uwe Lewandrowski MD  & Edward C. Benzel MD, FACS  & 

  3. University of Texas M. D. Anderson Cancer Center, Houston, TX

    Maurie Markman MD

  4. Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH

    Ronald M. Bukowski MD

  5. Department of Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, OH

    Roger Macklis MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press, Inc., Totowa, NJ

About this chapter

Cite this chapter

Kalmadi, S., Raghavan, D. (2006). Fundamentals of Cancer Treatment. In: McLain, R.F., Lewandrowski, KU., Markman, M., Bukowski, R.M., Macklis, R., Benzel, E.C. (eds) Cancer in the Spine. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59259-971-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-971-4_5

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-074-8

  • Online ISBN: 978-1-59259-971-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation